Search International and National Patent Collections

1. (WO2018104893) ALPHA4-BETA7 ANTIBODIES WITH INCRASED FCRN BINDING AND/OR HALF-LIFE

Pub. No.:    WO/2018/104893    International Application No.:    PCT/IB2017/057710
Publication Date: Fri Jun 15 01:59:59 CEST 2018 International Filing Date: Thu Dec 07 00:59:59 CET 2017
IPC: C07K 16/28
A61K 39/395
C12N 15/13
A61P 31/18
A61K 31/513
A61K 31/5365
A61K 31/675
Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Inventors: HONG, Zhi
JOHNS, Brian Alvin
GOUGH, Gerald Wayne
Title: ALPHA4-BETA7 ANTIBODIES WITH INCRASED FCRN BINDING AND/OR HALF-LIFE
Abstract:
The invention relates to novel α4β7antigen binding proteins. In particular, the invention relates to modified antigen binding proteins that are novel variants of anti-a4(37 antibodies, such as vedolizumab, which show increased binding to the FcRn receptor and/or increased half-life as compared to vedolizumab. Vedolizumab is an IgG1 monoclonal antibody comprising the light chain sequence of SEQ ID No: 7 and heavy chain sequence of SEQ ID No: 8. Methods as described herein comprise administering ART using compounds disclosed in Figure 4 and administering a modified antigen binding protein, for example a modified IgG α4β7 antibody such as a modified vedolizumab, having a variant Fc region with increased affinity to FcRn compared to unmodified antibody, resulting in sustained virologic control of the HIV infection in the subject - i.e. resulting in a cure or functional cure of the HIV infection in the subject.